Literature DB >> 16336624

Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Linda R Gowing1, Michael Farrell, Reinhard Bornemann, Lynn E Sullivan, Robert L Ali.   

Abstract

OBJECTIVE: To assess the effects of oral substitution treatment for opioid-dependent injecting drug users on HIV risk behaviors and infections. DATA SOURCES: Multiple electronic databases were searched. Reference lists of retrieved articles were checked.
METHODS: Because of varying methodologies of available studies, this systematic review was limited to a descriptive summary, looking at consistency of outcomes across studies.
RESULTS: Twenty-eight studies involving methadone treatment were included in the review. Methadone maintenance treatment is associated with statistically significant reductions in injecting use and sharing of injecting equipment. It is also associated with reductions in numbers of injecting drug users reporting multiple sex partners or exchanges of sex for drugs or money, but has little effect on condom use. It appears that the reductions in risk behaviors do translate into fewer cases of HIV infection.
CONCLUSIONS: Methadone maintenance treatment for injecting drug users significantly reduces the risk of transmission of HIV and should be provided as a component of a strategic approach to the prevention and control of HIV infection. There is insufficient evidence to determine whether other forms of oral substitution treatment also reduce the risk of HIV transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336624      PMCID: PMC1484643          DOI: 10.1111/j.1525-1497.2005.00287.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  28 in total

1.  Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study.

Authors:  M Gossop; J Marsden; D Stewart; A Rolfe
Journal:  Drug Alcohol Depend       Date:  2000-11-01       Impact factor: 4.492

2.  A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users.

Authors:  Arthur Margolin; S Kelly Avants; Lara A Warburton; Keith A Hawkins; Julia Shi
Journal:  Health Psychol       Date:  2003-03       Impact factor: 4.267

3.  Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.

Authors:  Lisa A Marsch; Warren K Bickel; Gary J Badger; Eric A Jacobs
Journal:  Drug Alcohol Depend       Date:  2005-02-14       Impact factor: 4.492

4.  Methadone maintenance as HIV risk reduction with street-recruited injecting drug users.

Authors:  C F Kwiatkowski; R E Booth
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

5.  Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome.

Authors:  J Strang; J Marsden; M Cummins; M Farrell; E Finch; M Gossop; D Stewart; S Welch
Journal:  Addiction       Date:  2000-11       Impact factor: 6.526

6.  Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment.

Authors:  V L King; M S Kidorf; K B Stoller; R K Brooner
Journal:  J Addict Dis       Date:  2000

7.  A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.

Authors:  Kate A Dolan; James Shearer; Margaret MacDonald; Richard P Mattick; Wayne Hall; Alex D Wodak
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

8.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.

Authors:  K L Sees; K L Delucchi; C Masson; A Rosen; H W Clark; H Robillard; P Banys; S M Hall
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  R P Mattick; C Breen; J Kimber; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 10.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  42 in total

1.  Impact of interim methadone maintenance on HIV risk behaviors.

Authors:  Monique E Wilson; Robert P Schwartz; Kevin E O'Grady; Jerome H Jaffe
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

2.  "We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine.

Authors:  Matthew J Mimiaga; Steven A Safren; Sergiy Dvoryak; Sari L Reisner; Richard Needle; George Woody
Journal:  AIDS Care       Date:  2010-11

3.  Adherence to HIV treatment and care among previously homeless jail detainees.

Authors:  Nadine E Chen; Jaimie P Meyer; Ann K Avery; Jeffrey Draine; Timothy P Flanigan; Thomas Lincoln; Anne C Spaulding; Sandra A Springer; Frederick L Altice
Journal:  AIDS Behav       Date:  2013-10

4.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

Review 5.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

7.  HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.

Authors:  George E Woody; Douglas Bruce; P Todd Korthuis; Sumedha Chhatre; Sabrina Poole; Maureen Hillhouse; Petra Jacobs; James Sorensen; Andrew J Saxon; David Metzger; Walter Ling
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

8.  The Chinese government's response to drug use and HIV/AIDS: a review of policies and programs.

Authors:  Jianhua Li; Toan H Ha; Cunmin Zhang; Hongjie Liu
Journal:  Harm Reduct J       Date:  2010-03-05

9.  Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

Authors:  David S Metzger; Deborah Donnell; David D Celentano; J Brooks Jackson; Yiming Shao; Apinun Aramrattana; Liu Wei; Liping Fu; Jun Ma; Gregory M Lucas; Marek Chawarski; Yuhua Ruan; Paul Richardson; Katherine Shin; Ray Y Chen; Jeremy Sugarman; Bonnie J Dye; Scott M Rose; Geetha Beauchamp; David N Burns
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

10.  Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment.

Authors:  Jo Kimber; Lorraine Copeland; Matthew Hickman; John Macleod; James McKenzie; Daniela De Angelis; James Roy Robertson
Journal:  BMJ       Date:  2010-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.